MP High Court Affirms White Petroleum Jelly as a 'Drug' for Tax Purposes

Bhopal, India – In a significant ruling that brings clarity to a long-standing tax classification dispute, the Madhya Pradesh High Court has held that White Petroleum Jelly of Indian Pharmacopoeia (IP) grade is to be classified as a 'drug' and not a 'cosmetic' for the purposes of Value Added Tax (VAT) and Entry Tax. The decision, delivered by a division bench of Justices Vivek Rusia and Jai Kumar Pillai in the case of M/s Hindustan Unilever Ltd. v. Commercial Taxes Department , quashes the higher tax liability imposed by state authorities and reaffirms the precedent set by the Supreme Court.

This judgment provides crucial relief to manufacturers and will have a ripple effect on the classification of similar products that possess both medicinal and general-use properties. By categorizing the product under the specific entry for "Drugs and medicines," the Court has allowed the appellant, Hindustan Unilever Ltd., to avail a significantly lower tax rate, settling a contentious issue that has journeyed through multiple levels of the tax adjudication system.

---

The Genesis of the Dispute: Classification and Tax Rates

The core of the legal battle revolved around the correct classification of "White Petroleum Jelly I.P." under the Madhya Pradesh VAT Act and the Entry Tax Act. The appellant, Hindustan Unilever Ltd., contended that its product, being a medicated formulation manufactured under a valid drug license, fell squarely within Entry No. 19A, Part II, Schedule II of the MP VAT Act, which pertains to “Drugs and medicines.”

This classification would entitle the company to a lower tax rate of 4% (up to July 31, 2009) and 5% thereafter. Furthermore, under the Entry Tax Act, this classification would render the product exempt from tax, as it would fall under Schedule III (non-taxable goods).

However, the state's assessing authority took a contrary view. It classified the product under the residuary entry as a 'cosmetic,' thereby subjecting it to a much higher VAT rate of 12% and an Entry Tax of 10%. The department's primary argument was that Hindustan Unilever is known as a manufacturer of cosmetics and toilet articles, not drugs. They further argued that White Petroleum Jelly is not typically prescribed by medical practitioners and is readily available in general stores, not just pharmacies, suggesting its primary use is cosmetic.

Aggrieved by this assessment, the company pursued appeals before the Additional Commissioner of Commercial Tax and subsequently the Commercial Tax Appellate Board, both of which upheld the assessing authority's decision, dismissing the company's claims.

---

The Weight of Precedent: The Ponds India Ltd. Ruling

A central pillar of the appellant's case before the High Court was the binding precedent set by the Supreme Court in Ponds India Ltd. v. Commissioner of Commercial Tax (2008). In that landmark case, the Apex Court had unequivocally held that White Petroleum Jelly of IP grade, when manufactured under a valid drug license, is indeed a 'drug' and not a 'cosmetic'.

The appellant, represented by Shri P.M. Choudhary, argued that the product's classification as a 'drug' is not merely a matter of commercial interpretation but is grounded in its statutory definition and confirmed by the highest court of the land. The fact that it is produced under a drug license and conforms to the standards of the Indian Pharmacopoeia solidifies its identity as a medicinal product.

The High Court bench took a dim view of the Commercial Tax Appellate Board's failure to adhere to this established legal principle. The bench noted, "...the M.P. Commercial Tax Board was not justified in [not] following the decision of the Apex Court in the case of Ponds India Ltd. vs. CCT (supra) ." This observation underscores a fundamental tenet of judicial discipline: the binding nature of precedents set by higher courts.

---

The Court's Analysis: Common Parlance vs. Statutory Definition

The High Court meticulously dissected the arguments presented by both sides. While acknowledging the department's 'common parlance' argument—that the product is sold in general stores without a prescription—the Court found it insufficient to override the product's technical and statutory classification.

The bench observed, "white Petroleum Jelly has some ingredients for caring and protection from specific skin problems, but it is not saleable as a beauty product." The judges distinguished between a product used for skin care and protection (medicinal) and one used for beautification (cosmetic).

Crucially, the Court examined the specific language of the MP VAT Act. Entry No. 19A explicitly includes "Drugs and medicines including vaccines, syringes, medicated ointments produced under drug license and light liquid paraffin of IP grade." The Court noted that White Petroleum Jelly IP contains light liquid paraffin of IP grade and is manufactured under a valid drug license. Therefore, it fits comfortably within the specific entry for drugs and medicines, leaving no room for it to be relegated to the general residuary entry for cosmetics.

The bench concluded that since the statute provides a specific entry for such products, the revenue department's attempt to classify it as a cosmetic was legally untenable.

---

Implications for the Industry and Legal Practice

The High Court's decision to quash the impugned order has several significant implications:

1. Reinforcement of Judicial Precedent: The ruling serves as a strong reminder to quasi-judicial and administrative bodies about their obligation to follow precedents laid down by the Supreme Court. The Board's deviation from the Ponds India Ltd. judgment was a key factor in the High Court's decision to overturn its order.

2. Clarity in Commodity Classification: This judgment provides much-needed clarity for the classification of products with dual-use characteristics. For tax law practitioners, it reinforces the principle that where a specific statutory entry exists, and a product meets its criteria (such as being manufactured under a drug license and conforming to pharmacopoeial standards), that specific entry must prevail over a general or residuary one.

3. Financial Relief for Manufacturers: For companies like Hindustan Unilever, the financial impact is substantial. The decision not only lowers their VAT and Entry Tax liability on future sales but also invalidates the higher tax demands and associated interest for the period under dispute. The Court explicitly stated, "the appellant is not liable to pay interest under Section 18(1)(a) of the MP VAT Act."

4. Guidance for Future Disputes: The case will serve as a persuasive authority in other states where similar classification disputes may arise. It highlights that the 'common parlance' test, while relevant, cannot be the sole determinant, especially when a product has a clear statutory and technical definition as a drug.

In conclusion, the Madhya Pradesh High Court's ruling is a well-reasoned decision that champions legal certainty and the rule of law. By aligning its judgment with the established Supreme Court precedent and conducting a precise interpretation of the relevant tax statutes, the Court has not only provided justice to the appellant but has also offered clear guidance for the classification of medico-cosmetic products in the complex landscape of indirect taxation.